CoChat

Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

A patient-derived CTC culture assay for anticancer drug evaluation to guide therapy for personalized treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.1600274

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic overview depicting the procedure for anticancer drug screening via conventional methods and the CTC cluster method. In the case of conventional methods, cancer cells are derived from commercialized cell lines or patient-derived CTCs and tumors. Establishment of CTC cell lines requires more than 6 months, and tumor sampling can only be carried out as a single sampling. In addition, pre-enrichment of CTCs is required before they can be cultured. Conversely, CTC clusters can be generated within 2 weeks, and the blood samples do not require pre-enrichment before culture. In this procedure, blood samples are first lysed briefly to remove red blood cells (RBCs), and the resultant nucleated cell fraction is seeded into an integrated microwell-based microfluidic assay. Drugs can be introduced directly in situ, and a microfluidic component helps to efficiently distribute a range of drug concentrations.
Fig. 1 Schematic overview depicting the procedure for anticancer drug screening via conventional methods and the CTC cluster method. In the case of conventional methods, cancer cells are derived from commercialized cell lines or patient-derived CTCs and tumors. Establishment of CTC cell lines requires more than 6 months, and tumor sampling can only be carried out as a single sampling. In addition, pre-enrichment of CTCs is required before they can be cultured. Conversely, CTC clusters can be generated within 2 weeks, and the blood samples do not require pre-enrichment before culture. In this procedure, blood samples are first lysed briefly to remove red blood cells (RBCs), and the resultant nucleated cell fraction is seeded into an integrated microwell-based microfluidic assay. Drugs can be introduced directly in situ, and a microfluidic component helps to efficiently distribute a range of drug concentrations.CC BY-NC · PubMed Central
Fig. 2 Establishment of CTC cluster assay for routine drug screening. (A) Three-dimensional layout of drug assay displaying the layers for the gradient generator, barrier, and microwells. (B) Gradient distribution of input reagents demonstrated by blue and red dyes. (C) (Left) Representative images of negative and positive samples. Bright-field images of microwells comprising a negative sample at ×10 magnification. Scale bar, 100 μm. (Middle) Hoechst staining of clusters in situ. Negative samples generated debris with some residual white blood cells (WBCs). Scale bar, 50 μm. (Right) Combined scatterplots of gray values, which reflected the density of cells, across each microwell. Values were normalized to the highest count for a particular microwell. Microwells with sparse groups of cells or debris demonstrated high gray values within the microwell region. (D) (Left) Bright-field images of microwells comprising a positive sample at ×10 magnification. Scale bar, 100 μm. (Middle) Nuclei staining using Hoechst on cell clusters in situ. Positive samples generated clusters with some residual WBCs. Scale bar, 50 μm. (Right) Combined scatterplots of gray values, with values normalized to the highest count for a particular microwell. Microwells with dense cell clusters demonstrated consistently low gray values (<0.5) within the microwell region.
Fig. 2 Establishment of CTC cluster assay for routine drug screening. (A) Three-dimensional layout of drug assay displaying the layers for the gradient generator, barrier, and microwells. (B) Gradient distribution of input reagents demonstrated by blue and red dyes. (C) (Left) Representative images of negative and positive samples. Bright-field images of microwells comprising a negative sample at ×10 magnification. Scale bar, 100 μm. (Middle) Hoechst staining of clusters in situ. Negative samples generated debris with some residual white blood cells (WBCs). Scale bar, 50 μm. (Right) Combined scatterplots of gray values, which reflected the density of cells, across each microwell. Values were normalized to the highest count for a particular microwell. Microwells with sparse groups of cells or debris demonstrated high gray values within the microwell region. (D) (Left) Bright-field images of microwells comprising a positive sample at ×10 magnification. Scale bar, 100 μm. (Middle) Nuclei staining using Hoechst on cell clusters in situ. Positive samples generated clusters with some residual WBCs. Scale bar, 50 μm. (Right) Combined scatterplots of gray values, with values normalized to the highest count for a particular microwell. Microwells with dense cell clusters demonstrated consistently low gray values (<0.5) within the microwell region.CC BY-NC · PubMed Central
Fig. 3 Comparison of custom tapered microwells fabricated using diffuser back-side lithography for CTC cluster assay and conventional cylindrical microwells. (A) Fabrication procedure: elliptical openings defining the size and position of the wells created on a soda-lime optical mask blank by laser direct writing. Subsequent Cr etching and stripping of the remaining resist were followed by coating with a layer of SU-8 2100 resist. Ultraviolet (UV) exposure to obtain pillar-like structures with the elliptical footprint and elliptical cross-shaped structures. Postbaking, ultrasound bath, and hard baking resulted in a template ready for PDMS molding. (B) (Left) Culture of MCF-7 in custom tapered microwells and cylindrical microwells. Single clusters were consistently established with tapered microwells. Scale bars, 50 μm. (C) (Left) Culture of clinical blood samples in custom tapered microwells and cylindrical microwells. Only debris was formed in cylindrical microwells. Scale bars, 50 μm. (Right) Combined scatterplots of gray values, with values normalized to the highest count for a particular microwell. Cylindrical microwells did not generate clusters, whereas tapered microwells led to a single dense cell cluster as observed from the region of low gray value. (D) Bar graph presenting results from a viability assay using trypan blue staining. Percentage of cells negative for trypan blue (viable cells) was significantly lower in the sample portion cultured in cylindrical microwells. All error bars represent SD of triplicate cultures from different samples. **P < 0.01.
Fig. 3 Comparison of custom tapered microwells fabricated using diffuser back-side lithography for CTC cluster assay and conventional cylindrical microwells. (A) Fabrication procedure: elliptical openings defining the size and position of the wells created on a soda-lime optical mask blank by laser direct writing. Subsequent Cr etching and stripping of the remaining resist were followed by coating with a layer of SU-8 2100 resist. Ultraviolet (UV) exposure to obtain pillar-like structures with the elliptical footprint and elliptical cross-shaped structures. Postbaking, ultrasound bath, and hard baking resulted in a template ready for PDMS molding. (B) (Left) Culture of MCF-7 in custom tapered microwells and cylindrical microwells. Single clusters were consistently established with tapered microwells. Scale bars, 50 μm. (C) (Left) Culture of clinical blood samples in custom tapered microwells and cylindrical microwells. Only debris was formed in cylindrical microwells. Scale bars, 50 μm. (Right) Combined scatterplots of gray values, with values normalized to the highest count for a particular microwell. Cylindrical microwells did not generate clusters, whereas tapered microwells led to a single dense cell cluster as observed from the region of low gray value. (D) Bar graph presenting results from a viability assay using trypan blue staining. Percentage of cells negative for trypan blue (viable cells) was significantly lower in the sample portion cultured in cylindrical microwells. All error bars represent SD of triplicate cultures from different samples. **P < 0.01.CC BY-NC · PubMed Central
Fig. 4 Assay validation with controls. (A) Screening of doxorubicin in microwell assay using MCF-7 cancer cell line. Cultures were imaged in situ after staining with LIVE (calcein-AM; green) and DEAD [ethidium bromide (EtBr); red] under 72 hours of exposure to doxorubicin. Clusters under high drug concentrations are mostly nonviable (red), whereas clusters under low drug concentrations are mostly viable (green). (B) Dose-response curve and corresponding IC50 value (0.78 ± 0.02 μM) of MCF-7 generated from viability results. Representative image shows an MCF-7 cell cluster within a microwell (inset). Scale bars, 50 mm. (C) Scatterplot demonstrating overall high gray values that reflect the absence of clusters from cultures of blood from healthy volunteers. Representative image shows cell debris generated within a microwell from culture of a healthy sample (inset). Scale bars, 50 mm.
Fig. 4 Assay validation with controls. (A) Screening of doxorubicin in microwell assay using MCF-7 cancer cell line. Cultures were imaged in situ after staining with LIVE (calcein-AM; green) and DEAD [ethidium bromide (EtBr); red] under 72 hours of exposure to doxorubicin. Clusters under high drug concentrations are mostly nonviable (red), whereas clusters under low drug concentrations are mostly viable (green). (B) Dose-response curve and corresponding IC50 value (0.78 ± 0.02 μM) of MCF-7 generated from viability results. Representative image shows an MCF-7 cell cluster within a microwell (inset). Scale bars, 50 mm. (C) Scatterplot demonstrating overall high gray values that reflect the absence of clusters from cultures of blood from healthy volunteers. Representative image shows cell debris generated within a microwell from culture of a healthy sample (inset). Scale bars, 50 mm.CC BY-NC · PubMed Central
Fig. 5 Screening of doxorubicin in microwell assay using clinical human primary cancer cells cultured from clinical samples at serial time points (before and after treatment). (A) Imaging of clusters generated from the pretreatment sample in situ after staining with LIVE (calcein-AM; green) and DEAD (EtBr; red) after 72 hours of exposure to doxorubicin. Clusters under high drug concentrations were mostly nonviable (red), whereas clusters under low drug concentrations were mostly viable (green). Scale bars, 100 μm. (B) Dose-response curve and corresponding IC50 value (0.94 ± 0.04 μM) of samples obtained from the same patient at different treatment time points. Monitoring IC50 values of a patient could reveal onset of drug tolerance or resistance. All error bars represent SD of triplicate cultures from different samples.
Fig. 5 Screening of doxorubicin in microwell assay using clinical human primary cancer cells cultured from clinical samples at serial time points (before and after treatment). (A) Imaging of clusters generated from the pretreatment sample in situ after staining with LIVE (calcein-AM; green) and DEAD (EtBr; red) after 72 hours of exposure to doxorubicin. Clusters under high drug concentrations were mostly nonviable (red), whereas clusters under low drug concentrations were mostly viable (green). Scale bars, 100 μm. (B) Dose-response curve and corresponding IC50 value (0.94 ± 0.04 μM) of samples obtained from the same patient at different treatment time points. Monitoring IC50 values of a patient could reveal onset of drug tolerance or resistance. All error bars represent SD of triplicate cultures from different samples.CC BY-NC · PubMed Central
Fig. 6 Proposed workflow of routine anticancer treatment evaluation with clinical human CTC cultures. Cluster formation potential correlates inversely with overall patient survival, and increased IC50 values suggest possible onset of drug tolerance or resistance. The procedure can be completed within 2 weeks and will aid the clinician’s decision of maintaining or altering a patient’s drug regimen.
Fig. 6 Proposed workflow of routine anticancer treatment evaluation with clinical human CTC cultures. Cluster formation potential correlates inversely with overall patient survival, and increased IC50 values suggest possible onset of drug tolerance or resistance. The procedure can be completed within 2 weeks and will aid the clinician’s decision of maintaining or altering a patient’s drug regimen.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 2

  1. 10.1111/j.1572-0241.2000.02091.x · doi:10.1111/j.1572-0241.2000.02091.x · Paper page
  2. I. J. Fidler, Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iodo-2’-deoxyuridine. J. Natl. Cancer Inst. 45, 773–782 (1970).

Cited by

Metadata

Authors
Khoo, B. L., Grenci, G., Jing, T., Lim, Y. B., Lee, S. C., Thiery, J. P., Han, J., & Lim, C. T.
Affiliations
  • Singapore-MIT Alliance for Research and Technology (SG)
  • National University of Singapore (SG)
Corresponding author
Lim, Chwee Teck
Venue
Science Advances
Published
2016-07
Volume
2
Issue
7
Pages
e1600274-e1600274
ISSN
2375-2548 (ISSN-L)
OpenAlex
W2471117482
Cited by
147
References
52
Citations by year
2026: 4 · 2025: 7 · 2024: 11 · 2023: 19 · 2022: 21 · 2021: 11 · 2020: 19 · 2019: 22 · 2018: 14 · 2017: 15 · 2016: 4
FWCI
8.84
Type
journal article
Language
en
Open access
Locations
  • Science Advances (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • Mechanobiology Institute (ID0ETJBI8533)
  • Singapore-MIT Alliance for Research and Technology (ID0EXPBI8534)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Bio-sensing Technologies
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
liquid biopsy, circulating tumor cells, CTC clusters, drug response monitoring, anticancer drug screening, metastatic breast cancer, microfluidics, drug resistance, precision oncology
MeSH terms
Antineoplastic Agents, Biopsy, Breast Neoplasms, Doxorubicin, Female, Humans, Neoplastic Cells, Circulating, Neoplasm Metastasis, Tumor Cells, Cultured, In Situ Hybridization, Fluorescence, Cell Culture Techniques, Microfluidic Analytical Techniques, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.